New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
Anthony D D’Urzo,1 Mario Cazzola,2 Nicola A Hanania,3 Roland Buhl,4 M Reza Maleki-Yazdi5 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, I...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-09-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/new-developments-in-optimizing-bronchodilator-treatment-of-copd-a-focu-peer-reviewed-article-COPD |
| _version_ | 1818479493618073600 |
|---|---|
| author | D'Urzo AD Cazzola M Hanania NA Buhl R Maleki-Yazdi MR |
| author_facet | D'Urzo AD Cazzola M Hanania NA Buhl R Maleki-Yazdi MR |
| author_sort | D'Urzo AD |
| collection | DOAJ |
| description | Anthony D D’Urzo,1 Mario Cazzola,2 Nicola A Hanania,3 Roland Buhl,4 M Reza Maleki-Yazdi5 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy; 3Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 4Pulmonary Department, Mainz University Hospital, Mainz, Germany; 5Division of Respiratory Medicine, Women’s College Hospital, University of Toronto, Toronto, ON, Canada Abstract: COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formoterol fumarate 18/9.6 µg formulated using innovative co-suspension delivery technology for administration via metered dose inhaler (MDI). GFF MDI was developed to make a treatment option available for patients who have a requirement or preference to use an MDI, rather than a dry powder or soft mist inhaler. Now that several LAMA/LABA FDCs have been approved for use in COPD, we review the impact of dual-bronchodilator treatment on COPD therapy and discuss recent clinical studies that are helping to develop a more comprehensive understanding of how LAMA/LABA FDCs can improve patient outcomes. Keywords: long-acting bronchodilator, LAMA, LABA, chronic obstructive pulmonary disease, fixed-dose combination, GFF MDI |
| first_indexed | 2024-12-10T11:11:19Z |
| format | Article |
| id | doaj.art-3c3918345860463d8fca20a29215add7 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-10T11:11:19Z |
| publishDate | 2018-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-3c3918345860463d8fca20a29215add72022-12-22T01:51:24ZengDove Medical PressInternational Journal of COPD1178-20052018-09-01Volume 132805281940442New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technologyD'Urzo ADCazzola MHanania NABuhl RMaleki-Yazdi MRAnthony D D’Urzo,1 Mario Cazzola,2 Nicola A Hanania,3 Roland Buhl,4 M Reza Maleki-Yazdi5 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy; 3Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 4Pulmonary Department, Mainz University Hospital, Mainz, Germany; 5Division of Respiratory Medicine, Women’s College Hospital, University of Toronto, Toronto, ON, Canada Abstract: COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formoterol fumarate 18/9.6 µg formulated using innovative co-suspension delivery technology for administration via metered dose inhaler (MDI). GFF MDI was developed to make a treatment option available for patients who have a requirement or preference to use an MDI, rather than a dry powder or soft mist inhaler. Now that several LAMA/LABA FDCs have been approved for use in COPD, we review the impact of dual-bronchodilator treatment on COPD therapy and discuss recent clinical studies that are helping to develop a more comprehensive understanding of how LAMA/LABA FDCs can improve patient outcomes. Keywords: long-acting bronchodilator, LAMA, LABA, chronic obstructive pulmonary disease, fixed-dose combination, GFF MDIhttps://www.dovepress.com/new-developments-in-optimizing-bronchodilator-treatment-of-copd-a-focu-peer-reviewed-article-COPDlong-acting bronchodilatorLAMALABAchronic obstructive pulmonary diseasefixed-dose combinationGFF MDI. |
| spellingShingle | D'Urzo AD Cazzola M Hanania NA Buhl R Maleki-Yazdi MR New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology International Journal of COPD long-acting bronchodilator LAMA LABA chronic obstructive pulmonary disease fixed-dose combination GFF MDI. |
| title | New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology |
| title_full | New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology |
| title_fullStr | New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology |
| title_full_unstemmed | New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology |
| title_short | New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology |
| title_sort | new developments in optimizing bronchodilator treatment of copd a focus on glycopyrrolate formoterol combination formulated by co suspension delivery technology |
| topic | long-acting bronchodilator LAMA LABA chronic obstructive pulmonary disease fixed-dose combination GFF MDI. |
| url | https://www.dovepress.com/new-developments-in-optimizing-bronchodilator-treatment-of-copd-a-focu-peer-reviewed-article-COPD |
| work_keys_str_mv | AT durzoad newdevelopmentsinoptimizingbronchodilatortreatmentofcopdafocusonglycopyrrolateformoterolcombinationformulatedbycosuspensiondeliverytechnology AT cazzolam newdevelopmentsinoptimizingbronchodilatortreatmentofcopdafocusonglycopyrrolateformoterolcombinationformulatedbycosuspensiondeliverytechnology AT hananiana newdevelopmentsinoptimizingbronchodilatortreatmentofcopdafocusonglycopyrrolateformoterolcombinationformulatedbycosuspensiondeliverytechnology AT buhlr newdevelopmentsinoptimizingbronchodilatortreatmentofcopdafocusonglycopyrrolateformoterolcombinationformulatedbycosuspensiondeliverytechnology AT malekiyazdimr newdevelopmentsinoptimizingbronchodilatortreatmentofcopdafocusonglycopyrrolateformoterolcombinationformulatedbycosuspensiondeliverytechnology |